Director Sandor Victor Receives Stock Options in Kymera Therapeutics

This SEC Form 4 filing reports that Sandor Victor, a director of Kymera Therapeutics, Inc., received a grant of 6,068 stock options on June 24, 2026. The options have an exercise price of $99.87 per share and expire on June 23, 2036. According to footnote F1, the shares underlying these stock options will vest in full upon the earlier of either June 24, 2027 or the date of the company's next annual meeting of stockholders. The transaction was reported as an award of derivative securities (transaction code A) with a price per share of $0, which is typical for stock option grants. Following this transaction, Victor holds 6,068 stock options. The filing was signed by Bruce Jacobs as attorney-in-fact on June 25, 2026.